Anushua Sinha MD
Associate Professor, Preventive Medicine & Community Health, UMDNJ-New
Join to view full profile
185 S Orange AveNew Jersey Medical School - Umdnj, Msb F506Newark, NJ 07103
Phone+1 973-972-4422
Fax+1 973-972-7625
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 6 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Anushua Sinha, MD is an infectious disease specialist in Newark, New Jersey. She is currently licensed to practice medicine in New Jersey. She is an Associate Professor at UMDNJ-New.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 1997 - 2001- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1992 - 1996
Harvard Medical SchoolClass of 1992
Certifications & Licensure
NJ State Medical License 2005 - 2021
Publications & Presentations
PubMed
- 30 citationsA Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.Shabir A Madhi, Eric A F Simões, Armando Acevedo, Jose M Novoa Pizarro, Julie S Shepard
The Journal of Infectious Diseases. 2025-03-17 - 59 citationsCervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review.Wei Wang, Emanuele Arcà, Anushua Sinha, Kristina Hartl, Natalie Houwing
Preventive Medicine Reports. 2022-08-01 - 5 citationsHealth Care Resource Utilization and Economic Burden Associated With Congenital Cytomegalovirus Infection: A Longitudinal Analysis of Data From Clinical Practice at a ...Clara Weil, Wei Vivian Wang, Morgan A Marks, Efraim Bilavsky, Anushua Sinha
Clinical Therapeutics. 2022-02-01
Press Mentions
New ACIP Panel Votes to Recommend Clesrovimab, Second Antibody to Prevent RSV in InfantsJune 26th, 2025- Novel Monoclonal Antibody Protects Infants Against RSVOctober 19th, 2024
- Second Season of Clesrovimab for RSV Well Tolerated in High-Risk KidsJuly 28th, 2026